Superworth

Aethlon Medical revenue AEMD

Sales by quarter and over the last twelve months, from 2011.

Last 12 months, to Mar 31, 2023
$574.2K
Latest quarter, Q4 FY23
$574.2K
+4278% on a year earlier
Fiscal year 2023
$574.2K
+95% on the year before

Aethlon Medical's revenue was $574.2K over the twelve months to Mar 31, 2023, up 95% on a year earlier.

In its latest quarter, Q4 FY23, it was $574.2K, up 4278% on the same quarter a year before.

Over the five fiscal years to FY2023 it grew 31% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2023$574.2K+95%
FY2022$294.2K−55%
FY2021$659.1K+1%
FY2020$650.2K+183%
FY2019$229.6K+53%
FY2018$149.6K−80%
FY2015$762.4K−53%
FY2014$1.6M+32%
FY2013$1.2Mn/a
FY2012n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY23$574.2K+4278%$574.2K
Q3 FY23$0−100%$13.1K
Q2 FY23$0−100%$30.2K
Q1 FY23$0−100%$162.2K
Q4 FY22$13.1K−62%$294.2K
Q3 FY22$17.1K−97%$315.3K
Q2 FY22$132Kn/a$923K
Q1 FY22$132Kn/a$791.1K
Q4 FY21$34.2K−83%$659.1K
Q3 FY21$624.9K+51%$831.6K
Q2 FY21$0n/a$620.2K
Q1 FY21$0−100%$620.2K

Against its peers

Companies in Healthcare nearest Aethlon Medical's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
AEMDAethlon Medicaln/m
OXBROXBRIDGE RE HOLDINGS$2.8M+40% a year
EDUCEducational Development$20M−32% a year
GTIMGood Times Restaurants$135.1M−6% a year
MDRRMedalist Diversified$9.6M−1% a year
BCGBinah Capital$191.9M+8% a year
VIPVulcan Infrastructure & Power$50.9M−14% a year
MXCMexco Energy$6.7M−9% a year
CKXCKX Lands$693.4K−17% a year
MSGMMotorsport Games$14.5M+79% a year
ATCHAtlasClear$20.1M+85% a year
Peer median$17.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Aethlon Medical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.